TheFly.com
NERV
Minerva
$
()
Minerva trading resumes
Minerva trading halted, volatility trading pause
Minerva receives complete response letter from FDA for NDA for roluperidone
Minerva reports Q4 EPS ($1.19) vs. ($1.26) last year
Minerva reports Q3 EPS ($1.03) vs. ($1.29) last year
Minerva files to sell 2M shares of common stock for holders
Minerva reports Q2 EPS ($1.12) vs. ($1.63) last year
Minerva prices 1.425M shares at $10.00 in private placement
Minerva reports Q1 EPS ($1.31) vs ($1.83) last year
Minerva announces update on NDA for roluperidone
Minerva announces U.S. FDA filed NDA for roluperidone
Copyright ©1998-2024 Thefly.com LLC
